Platzbecker U, Della Porta MG, Santini V, Zeidan AM, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet 2023 Jun 9:S0140-6736(23)00874-7. doi: 10.1016/S0140-6736(23)00874.
PMID: 37311468